How is it possible to take the worst performing stock on the S&P 500 even lower? Well, first the S&P kicks you (ENDP) off the 500. Then you (Paul) skyrocket the salary expense line by packaging any executive leadership that didn't come from Par. On the Malvern side since 1/1/16: new CEO and CFO, Julie gone (okay, that was fine), 3 Branded presidents, 3 heads of comm ops, 3(?) business unit leads gone, turn over VP of managed markets, remove both specialty sales leaders, remove CIO and one of the CIO's VPs, remove head of R&D and 2 of her VPs...I know I am forgetting some people. Also, since Paul assumed leadership, Endo has failed on a pain product launch and reduced the sales force by about 400 (of 600 - and that reduction is a smaller percentage than what the stock has fallen over the last year). And, with all this turnover, Paul can also take the worst performing stock on the S&P 500 (well, formerly on it) and get the price to drop another 40+% so far in 2017. So, waiting for the cellulite trial to get to a later stage before dumping branded or will you go private before that (with the stock this low, easier to go private huh?)?
